The Genetic Basis of Human Height: Week 1 Reading Notes
Box 1 | Skeletal development and longitudinal growth
Human skeletal growth occurs through two ossification processes: intramembranous ossification (flat bones of skull, part of clavicle, cranial bones) and endochondral ossification (major mechanism for long bones).
Longitudinal growth mainly occurs at the growth plates (physes) of long bones and is driven by chondrogenesis: formation of a cartilage template that is later replaced by bone.
Growth plate organization (zones): resting zone (slow cell cycle, progenitor pool) → proliferative zone (differentiating and proliferating chondrocytes) → hypertrophic zone (chondrocyte enlargement and maturation, secretion of extracellular matrix) → mineralization zone (calcified matrix; restricted diffusion, chondrocyte apoptosis, invasion by blood vessels that bring osteoblasts).
Growth plate activity is regulated by a network of systemic and local signals, including genetic factors, nutrition, hormones (e.g., GH/IGF axis), inflammatory cytokines, paracrine growth factors, extracellular matrix components, and intracellular proteins.
Growth plate activity persists until epiphyses fuse with metaphysis, terminating bone lengthening.
Short stature in many genetic skeletal conditions results from downregulation of proliferation or hypertrophy of growth plate chondrocytes; tall stature results from enhanced chondrogenesis.
Box 1 illustrates the key biology of endochondral bone growth and the growth plate’s role in determining final stature.
Introduction | Origins and architecture of height genetics
Height is a model polygenic trait: additive effects of many variants produce continuous variation in stature; extremes can result from single-gene (monogenic) variants.
Height is epidemiologically relevant: taller individuals have higher cancer risk; shorter stature is linked to higher risk of coronary heart disease and diabetes mellitus.
Technological advances (SNP arrays, gene panels, whole-exome sequencing, whole-genome sequencing) enabled systematic dissection of height genetics.
Monogenic height disorders: hundreds of disorders with stature as a clinical feature; OMIM lists >500 genes with pathogenic variants causing short or tall stature.
Polygenic height architecture: large-scale GWAS have identified common height alleles contributing to high heritability; height GWAS has reached saturation in European-ancestry populations.
This Review integrates monogenic and polygenic views, highlighting pathways that influence growth plate function and stature.
Monogenic conditions linked to height | Overview
Monogenic height disorders are categorized as syndromic (with additional features beyond height) or non-syndromic (height changes are isolated).
Disorders can cause proportionate or disproportionate stature (e.g., limb-shortening dysplasias vs. uniform short stature).
Growth-related disorders often exert primary effects at the growth plate but can involve broader developmental processes.
Major subgroup: growth hormone (GH) and IGF axis disorders (GH signaling components: GH1, IGF1, IGF2, IGF1R, GHR, STAT3, STAT5, IGFALS).
GH signaling: GH receptor activation promotes IGF1/IGF2 synthesis; GH also has direct effects on local IGF1 production at the growth plate.
Classic example: Laron syndrome (GH receptor deficiency) with severe postnatal growth retardation but relatively decreased cancer risk in some studies.
Other GH axis disorders: insufficiencies or mutations in GH pathway components lead to short stature with proportional body features.
Growth-plate–targeted signaling defects include FGFR3-related conditions (achondroplasia, hypochondroplasia, thanatophoric dysplasia), NPR2/CNP signaling, PTH/PTHrP signaling (PTH1R), Indian hedgehog (IHH), ACAN (aggrecan) defects, and more.
Achondroplasia (FGFR3 gain-of-function) causes disproportionate short stature with characteristic increased upper-to-lower body segment ratio and potential neurological complications due to foramen magnum/spinal canal stenosis.
Hypochondroplasia and lethal thanatophoric dysplasia are FGFR3-related disorders with varying severity.
FGFR3 pathway abnormalities may underlie familial short stature beyond classic skeletal dysplasias.
Other skeletal dysplasias involve TGFβ/BMP signaling (e.g., NPR2/NPR3/CNP pathway) and influence chondrocyte proliferation/differentiation via cGMP and MAPK signaling,
illustrating bidirectional effects on growth depending on signaling intensity.IHH (Indian hedgehog) participates in a feedback loop with PTHrP to regulate endochondral ossification; biallelic IHH variants cause acrocapitofemoral dysplasia with severe short stature; monoallelic variants linked to familial short stature.
ACAN (aggrecan) mutations are a common cause of familial short stature, sometimes isolated or syndromic, reflecting ECM roles in growth plate stability and signaling cross-talk with IHH and FGFR3.
Primordial dwarfism (MPD) describes autosomal recessive disorders with severely reduced height and proportionate body size; PCNT mutations underlie MPD type II, disrupting centrosomes and mitotic spindle function, with disorganized growth plate histology observed in animal models.
MPD genes often affect DNA replication, replication stress responses, and cell cycle progression (e.g., ORC1, ORC4, ORC6, CDT1, CDC6, MCM5, MCM7, CDC45, GINS2, GINS3, DONSON; ATR/ATRIP, CHK1).
DNA replication and damage response pathways are linked to growth disorders; perturbations can reduce global proliferation and specifically impact growth plate dynamics.
Isolated short stature includes SHOX haploinsufficiency (Leri–Weill dyschondrosteosis when combined with skeletal anomalies) and other genes with modest effects; many instances reflect polygenic contributions with small effects size per variant.
Diagnostic yield for isolated short stature remains limited; monogenic causes explained in a minority, with many cases likely due to polygenic variation.
Isolated short stature and genomic conditions altering height | Genomic context
Chromosomal disorders commonly alter height (e.g., Down syndrome, Turner syndrome) due to involvement of multiple genes; genotype–phenotype relationships can be complex.
Copy number variants (CNVs) contribute to genomic conditions with variable height phenotypes; ~20% of CNV-associated conditions include short or tall stature.
SHOX gene (X/Y pseudoautosomal region) exemplifies gene-to-phenotype specificity: SHOX haploinsufficiency causes Turner syndrome short stature; extra copy of SHOX in other X-chromosome–related aneuploidies can contribute to tall stature.
Most CNV-driven height effects arise from multi-genic contexts; precise mechanisms often involve cumulative effects across pathways within the growth plate.
Short stature and tall stature: Examples | Pathways and syndromes
Tall stature disorders: Marfan syndrome (FBN1) is a leading example; abnormal fibrillin-1 affects connective tissue, ECM, and perichondrium function, shaping bone growth.
Simpson–Golabi–Behmel syndrome (GPC3 or GPC4 loss-of-function) causes X-linked overgrowth with intellectual disability; glypicans regulate key growth pathways (Wnt, BMP, FGF).
Epigenetic regulators: loss-of-function variants in PRC2 components (EED Cohen–Gibson syndrome; SUZ12 Imagawa–Matsumoto syndrome; EZH2 Weaver syndrome) produce tall stature; PRC2 methylates H3K27 to regulate transcription; epi-signatures in blood reflect shared pathophysiology.
NSD1 (Sotos syndrome) is a major overgrowth condition; haploinsufficiency leads to tall stature (and sometimes variable height). SETD2 haploinsufficiency can cause tall stature but with high phenotypic variability.
Other chromatin remodelers (SWI/SNF subunits) and transcriptional regulators (CHD8, HIST1H1E, NFIX) show tall stature as a feature among broader neurological phenotypes.
DNMT3A mutations cause Tatton-Brown–Rahman overgrowth through global hypomethylation; variants in the PWWP domain can cause Heyn–Sproul–Jackson syndrome, with opposite methylation effects and MPD phenotypes.
NSD1 duplications, in contrast to Sotos syndrome deletions, can cause reduced growth, illustrating bidirectional effects of the same gene on stature.
Bidirectional disease mechanisms are common across height-regulating pathways, highlighting the value of pathway-level analysis for therapeutic targeting.
Polygenic contributors to human height | The bulk of heritability and GWAS findings
Heritability of height is high; estimates suggest (80% or more) in relatively homogeneous populations.
Common variants explain about half of the phenotypic variance and roughly half of height heritability attributable to genetics in many populations; fine-scale partitioning shows enrichment near relevant genes.
GWAS landscape: the GIANT consortium identified about independent height-associated signals at common variants reaching genome-wide significance (P<5\times 10^{-8}) across >5 million participants, including >1{,}000 individuals with non-European ancestry.
Additive effects of these common height variants account for the majority (>80%) of heritability captured by common variation in Europeans; polygenic scores that include sub-significant variants can explain nearly all common-variant heritability in European ancestry groups.
Partitioning heritability shows signals cluster in regions of the genome; about of the genome (within ~ of height-associated variants) explains nearly all common-variant heritability, suggesting concentrated biological signaling in these regions.
GWAS signals are frequently non-coding, making it challenging to identify causal genes; rare non-coding variants identified by whole-genome sequencing also influence height via gene regulation.
Many GWAS loci lie near genes involved in skeletal growth (including monogenic height genes); some loci point to novel biology beyond known height genes.
To map GWAS hits to biology, additional functional studies (CRISPR screens, transcriptomics, epigenomics) and other genetic studies are needed to connect non-coding signals to effector genes and mechanisms affecting the growth plate.
Rare coding variants also contribute to height: exome-focused studies find that aggregation tests (burden tests) across genes identify associations with height; among discovered genes, several overlap monogenic height disorders (e.g., ACAN, IHH, PTH1R); UK Biobank analyses show LOF variants in ~78 genes associated with height, of which ~18 are known monogenic height genes; many such genes sit near GWAS signals.
The “allelic spectrum” concept: genes can have variants from overwhelming rare/strong-effect mutations to rare coding variants to common non-coding variants, all influencing height through shared biology.
From genes to biology: common pathways in monogenic and complex regulators of height
Height-associated genes cluster into core biological processes that regulate growth plate chondrocyte biology and skeletal growth.
Growth plate biology as a hub: signaling, transcriptional regulation, cell cycle/proliferation, ECM composition, and systemic growth axis contributions.
Key signaling axes repeatedly implicated:
FGF/FGFR3 signaling: FGFR3 activation inhibits chondrocyte proliferation and matrix production via MAPK pathways; FGFR3 variants cause short stature (achondroplasia) but non-coding variants at FGFR3 can also modulate height via regulatory effects.
CNP–NPR2–cGMP axis: C-type natriuretic peptide (CNP) binding NPR2 raises cGMP, activating PKG and antagonizing MAPK signaling to promote chondrocyte growth; bidirectional height effects arise from CNP/NPR2 pathway alterations.
GH–IGF axis: GH stimulates IGF1/IGF2 production and direct local IGF1 at the growth plate; many height-associated genes are in GH/IGF signaling or its regulation.
PTH/PTHrP signaling: PTH1R governs growth plate differentiation and mineralization; variants can cause skeletal dysplasias (Blomstrand, Eiken) or influence height.
IHH–PTHrP feedback loop: IHH regulates proliferation/differentiation of chondrocytes in growth plate, interacting with PTHrP signaling to coordinate endochondral ossification.
ECM and proteoglycans: ACAN (aggrecan) variants disrupt ECM composition and growth plate signaling, affecting chondrocyte proliferation and signaling cross-talk with IHH/FGFR3.
Epigenetic regulation and chromatin remodeling as height modulators:
PRC2 complex (EED, SUZ12, EZH2) trims H3K27 methylation; reduced PRC2 activity reduces chondrocyte proliferation and hypertrophic differentiation, whereas gain-of-function can alter the epigenetic landscape to influence height; epi-signatures help diagnose variant effects.
DNMT3A mutations (Tatton-Brown–Rahman syndrome; Heyn–Sproul–Jackson syndrome) modulate DNA methylation, altering H3K27me3 PRC2 target gene regulation and stem cell states; bidirectional height effects depend on methylation patterns.
NSD1 alterations (Sotos syndrome; duplications) affect H3K36 methylation and intergenic DNMT3A recruitment, influencing height; SETD2 haploinsufficiency can cause tall stature with variable expressivity.
Chromatin remodelers and transcription regulators (CHD8, HIST1H1E, NFIX) show associations with height in addition to neurodevelopmental phenotypes, underscoring shared developmental biology.
Cell-cycle and mitosis regulators linked to MPD (e.g., PCNT, ATR, CENPJ, MCPH1) indicate a connection between global proliferative capacity and growth plate function; many MPD genes have broader body-size effects consistent with a general reduction in growth.
Growth plate biology integrates signals from multiple cellular layers; the same genes can influence height through diverse mechanisms, explaining bidirectional height effects and phenotypic variability.
Bidirectional regulation of height | Opposing height outcomes from the same pathways
Many height-related loci show bidirectional effects: variants can cause either short or tall stature depending on the direction of functional change.
FGFR3: activating variants cause short stature; reduced FGFR3 activity can contribute to tall stature in some contexts.
FBN1: variants across the gene can drive tall stature (Marfan) or short stature (Weill–Marchesani, congenital scleroderma) depending on mutation location and domain.
FBN2: mutations can yield acromelic dysplasia (short stature) or bidirectional effects on height depending on affected domains.
CNP–NPR2 axis: loss-of-function NPR2 or NPPC can cause short stature; overexpression or increased activity of NPR2/CNP can promote tall stature.
FGFR3–CNP–NPR2 interplay: pathway balance determines chondrocyte proliferation/differentiation; shifting activity toward CNP–NPR2 can rescue FGFR3-driven growth inhibition in model systems.
Mechanistic basis:
Altered signaling intensity or duration in growth plate pathways can yield opposite phenotypes, illustrating the pathway’s role as a master regulator of growth.
Epigenetic and transcriptional context (e.g., DNMT3A, NSD1) can reprogram cell states, contributing to bidirectional outcomes.
Therapeutic implications:
Bidirectional gene behavior can inform drug targeting; drugs that modulate these pathways may have enhanced likelihood of success if they can be tuned to produce beneficial directionality (e.g., CNP analogue vosoritide to promote growth in achondroplasia).
Targeting bidirectional nodes may yield greater therapeutic potential by enabling controlled modulation of growth plate activity.
Box 2 | Therapeutic strategies for height disorders | Vosoritide and related strategies
Vosoritide is a modified CNP analogue designed to have an extended half-life and enhance NPR2 signaling to promote endochondral growth and counteract FGFR3-driven inhibition in achondroplasia.
Conceptual basis:
Increased NPR2 activity raises cGMP, which inhibits MAPK signaling downstream of FGFR3, thereby promoting chondrocyte proliferation and maturation in the growth plate.
Therapeutic upregulation of the CNP–NPR2 axis can reconcile the opposing growth-inhibitory effects of FGFR3 variants, partially restoring bone growth.
Therapeutic implications across height disorders:
Bidirectional regulators (e.g., FGFR3, NPR2, CNP) represent attractive therapeutic targets; modulation can have disease-ameliorating effects or, in principle, height improvement in specific contexts.
Epigenetic regulators (EZH2, EED, SUZ12, DNMT3A, NSD1) and chromatin remodelers offer potential, but therapeutic targeting of chromatin modifiers requires caution due to broad effects; precision strategies are needed.
Broader future directions:
Integrating genetic and epigenetic information to tailor therapies by individual pathway perturbations.
Combining growth-modulating therapies with lifestyle or nutritional interventions may optimize height outcomes and associated health risks.
Conclusions and future perspectives | Key takeaways and forward-looking ideas
GWAS has produced a saturated map of height-associated loci, accounting for a substantial portion of heritability and incorporating diverse ancestries; however, many risk alleles in underrepresented populations remain to be discovered.
Increasing diversity in genomic studies is essential to identify novel variants and loci influencing height and to ensure equitable benefits from discoveries.
There is a strong reciprocal relationship between monogenic height genes and polygenic signals; monogenic discoveries guide interpretation of GWAS loci, and large-scale sequencing will illuminate the contribution of rare coding variants to height.
Large-scale sequencing and functional studies will continue to identify new height-related genes and refine causal mechanisms, enabling translation into targeted therapies.
Practical considerations for future work include: adopting FAIR and CARE principles for genetic studies, especially in Indigenous and underrepresented populations; improving fine-mapping to causal variants; connecting signals to effector genes in growth plate biology; and developing bidirectional, pathway-based therapeutic strategies (e.g., CNP–NPR2 modulation).
Overall, height biology emerges as a rich model of how many small genetic effects converge on a few core developmental pathways that regulate chondrocyte proliferation, differentiation, and growth plate function, shaping human stature across the full spectrum.
Table 1 | Examples of genes with both monogenic and polygenic links to height | Highlights
ACAN: aggrecan core protein; monogenic skeletal disorders include short stature; strong height GWAS associations near ACAN; ECM and signaling interplay with IHH/FGFR3.
FGFR3: FGFR3 gene; monogenic short-stature disorders (achondroplasia, hypochondroplasia, thanatophoric dysplasia); multiple GWAS signals at the locus influencing height in the general population.
GHR, GH1, IGF1, IGF1R, IGF2, IGFALS: components of GH–IGF axis; monogenic short stature variants exist; multiple GWAS signals across these genes reflect modular growth signaling.
NPR2 (NPR2) and NPPC: components of CNP–NPR2 pathway; biallelic variants can cause short stature; gain-of-function or overexpression can contribute to tall stature; a prominent pathway in bidirectional height regulation.
FBN1, FBN2: fibrillin family; mutations cause Marfan syndrome (tall stature) and related skeletal dysplasias with short stature in different contexts; bidirectional height effects observed.
NSD1, SETD2, EZH2, EED, SUZ12, DNMT3A: epigenetic regulators; associated with overgrowth (Sotos, Weaver, Tatton-Brown–Rahman); promoter/enhancer perturbations and chromatin state changes connect monogenic and polygenic height signals.
IHH, SHOX, PTH1R, NPPC, NPR2, ACAN, PTHR, and several MPD genes (e.g., PCNT, CEP63, MCPH1): illustrate the convergence of developmental, growth-plate, and replication/centrosomal pathways on stature.
The table and network illustrate how coding and non-coding variants across these genes intersect in monogenic height disorders and polygenic height variation.
Box 1 | Skeletal development and longitudinal growth (revisited)
Origin and fusion of growth plates allow linear growth during childhood and adolescence.
Endochondral ossification framework: cartilage template laid down by chondrocytes in growth plates and replaced by bone.
Growth plate zones and their roles:
Resting zone: reservoir of chondrocyte progenitors.
Proliferative zone: rapid chondrocyte division and matrix production.
Hypertrophic zone: chondrocyte enlargement and maturation; matrix remodeling.
Mineralization zone: calcified cartilage matrix, vascular invasion, osteoblast formation.
Regulation is multifactorial: genetic, nutritional, hormonal, inflammatory, extracellular matrix, and intracellular signaling inputs converge to determine lengthening pace.
Growth plate fusion marks end of height increase; timing varies by sex and genetic background.
Box 2 | Therapeutic strategies for height disorders (expanded)
Vosoritide as a therapeutic strategy targets CNP–NPR2 axis to counteract FGFR3-driven inhibition in achondroplasia.
Mechanism: CNP binding NPR2 raises intracellular cGMP, which inhibits MAPK signaling downstream of FGFR3, allowing continued chondrocyte proliferation and differentiation.
Therapeutic implications extend to bidirectional regulators; pathways that can be modulated to increase height or prevent disproportionate growth abnormalities hold translational potential.
Clinical translation requires careful consideration of long-term safety, off-target effects, and the balance between growth promotion and other tissue development.
Connections to prior lectures and real-world relevance
Height serves as a paradigm for polygenic trait architecture, illustrating how many small-effect variants and a subset of large-effect variants interact to shape a quantitative trait.
The growth plate is a central model for studying organ-scale developmental regulation, linking molecular signaling to tissue morphology and whole-body outcomes.
Clinically, height genetics informs risk stratification for cardiometabolic diseases and cancer, and informs therapeutic strategies for skeletal dysplasias.
Ethical considerations: representation of diverse populations in genetic studies; responsible communication of genetic risk and potential therapies; equitable access to benefits from genomic research.